In the presented study, among measured antioxidative enzymes, only CAT activity was comparable between the studied groups, whereas urine SOD and MnSOD activity was significantly higher among T2DM patients treated with SGLT2i compared to diabetic controls not receiving SGLT2i and to healthy controls. The gene discussed is SOD1; the disease is type 2 diabetes mellitus.